Expand LXRX Menu
LXRX MENU

LXRX Latest Press Releases

-- March 24, 2026 --

Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo Globe Newswire 8:00 AM

-- March 23, 2026 --

Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851 Globe Newswire 7:30 AM

-- March 11, 2026 --

Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes Globe Newswire 8:00 AM

-- March 5, 2026 --

Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates Globe Newswire 6:59 AM

-- March 3, 2026 --

Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight PRNewswire 5:31 PM
Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences Globe Newswire 4:01 PM

-- February 26, 2026 --

Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026 Globe Newswire 8:30 AM

-- February 6, 2026 --

Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement Globe Newswire 5:17 PM

-- January 30, 2026 --

Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement Globe Newswire 2:50 AM

-- January 29, 2026 --

Lexicon Announces Proposed Public Offering of Common Stock Globe Newswire 4:31 PM

-- January 23, 2026 --

Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary Globe Newswire 8:30 AM

-- January 21, 2026 --

Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain Globe Newswire 8:30 AM

-- January 20, 2026 --

Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa (Sotagliflozin) for the Treatment of Heart Failure PRNewswire 6:59 AM

-- January 12, 2026 --

Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference Globe Newswire 7:30 AM

-- January 9, 2026 --

Lexicon Pharmaceuticals Publishes "Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain" Globe Newswire 8:30 AM

-- January 7, 2026 --

Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference Globe Newswire 8:30 AM

-- December 10, 2025 --

Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851 Globe Newswire 8:30 AM

-- December 5, 2025 --

Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum Globe Newswire 8:30 AM

-- November 25, 2025 --

Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences Globe Newswire 8:30 AM

-- November 11, 2025 --

Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference Globe Newswire 8:30 AM

-- November 8, 2025 --

Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025 Globe Newswire 2:30 PM

-- November 6, 2025 --

Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates Globe Newswire 7:30 AM

-- November 4, 2025 --

Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association's Sessions 2025 in New Orleans Globe Newswire 8:30 AM

-- October 30, 2025 --

Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025 Globe Newswire 8:30 AM
Market Data Delayed 15 Minutes